Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Nxera Pharma, Apr-Jun (2Q) Net Income Loss Widens
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Nxera to Receive US$4.8 mn in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel OX2R Agonist
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Consolidated Financial Results for the Three months Ended March 31, 2025 (IFRS)
Nxera Pharma, Jan-Mar (1Q) Net Income Loss Narrows
Nxera’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Notice of Issuance of New Shares Under RSU Plan and Determination of Pmt Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Correction to “Notice Regarding Reduction of the Amount of Capital Reserve and Disposition of Surplus”